Hematological Malignancies

Hematological Malignancies Advances in BCMA-Targeting Therapies: Takeaways from ASH2024 Champions Oncology · December 11, 2024

Hematological Malignancies Development of Innovative Therapies Utilizing Preclinical CLL Models Champions Oncology · June 13, 2024

BTK inhibitors Advancing the Battle Against Mantle Cell Lymphoma Champions Oncology · March 8, 2024

Hematological Malignancies Triplet Therapy for IDH1-Mutant AML Tumors Champions Oncology · February 15, 2024

Hematological Malignancies A Needle in a Haystack: Finding Rare AML Populations by Flow Cytometry Champions Oncology · February 1, 2024

Hematological Malignancies Unlocking the Potential of CAR-T Therapy for Treatment of Multiple Myeloma Champions Oncology · January 19, 2024

Hematological Malignancies Advancing Therapeutic Strategies for Myelodysplastic Syndrome Champions Oncology · December 7, 2023

Hematological Malignancies Potentials of BTK Therapies for Chronic Lymphocytic Leukemia Champions Oncology · November 2, 2023

Hematological Malignancies Understanding Relapse & Acquired Resistance to CD19-targeted Therapies Champions Oncology · June 29, 2023

Hematological Malignancies Novel RNAs Insights Toward AML Development Champions Oncology · April 13, 2023

Hematological Malignancies Overcoming Drug Resistance in AML: Targeting Tricky Signaling Pathways Champions Oncology · March 30, 2023